{"id":827003,"date":"2025-03-18T09:18:41","date_gmt":"2025-03-18T13:18:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/"},"modified":"2025-03-18T09:18:41","modified_gmt":"2025-03-18T13:18:41","slug":"gri-bio-participates-in-a-virtual-investor-ceo-connect-segment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/","title":{"rendered":"GRI Bio Participates in a Virtual Investor CEO Connect Segment"},"content":{"rendered":"
\n

\n Access the CEO Connect segment\u00a0<\/em>
\n
\n here<\/em>
\n <\/a>\n <\/p>\n

\n LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) — <\/strong>
\n GRI Bio, Inc.<\/a>\u00a0(NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, President and CEO of GRI Bio participated in a Virtual Investor CEO Connect segment<\/a>.<\/p>\n

As part of this segment, Dr. Hertz provided an overview of GRI\u2019s lead program, GRI-0621, for Idiopathic Pulmonary Fibrosis (IPF), a rare chronic, progressive fibrosing interstitial lung disease with limited treatment options. Dr. Hertz highlighted near-term value driving milestones, such as interim data coming at the beginning of next quarter and topline data in the following quarter.<\/p>\n

The Virtual Investor CEO Connect featuring GRI Bio is now available here<\/a>. Additional videos from the \u201cWhat This Means\u201d series are available on demand at\u00a0https:\/\/virtualinvestorco.com\/gri\/<\/a>.<\/p>\n

\n About GRI Bio, Inc.<\/strong>\n <\/p>\n

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio\u2019s therapies are designed to target the activity of Natural Killer T (\u201cNKT\u201d) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (\u201ciNKT\u201d) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio\u2019s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (\u201cdNKT\u201d) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions. These forward-looking statements are based on the Company\u2019s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the timing and effectiveness of the Reverse Split; the Company\u2019s ability to regain compliance with the Nasdaq minimum bid price and other listing requirements; the Company\u2019s expectations with respect to development and commercialization of the Company\u2019s product candidates; the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company\u2019s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company\u2019s common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company\u2019s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company\u2019s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company\u2019s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company\u2019s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company\u2019s filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), including the risks and uncertainties described in the \u201cRisk Factors\u201d section of the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.<\/p>\n

\n Investor Contact:<\/strong>\n <\/p>\n

JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Access the CEO Connect segment\u00a0 here LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc.\u00a0(NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, President and CEO of GRI Bio participated in a Virtual Investor CEO Connect segment. As part of this segment, Dr. Hertz provided an overview of GRI\u2019s lead program, GRI-0621, for Idiopathic Pulmonary Fibrosis (IPF), a rare chronic, progressive fibrosing interstitial lung disease with limited treatment options. Dr. Hertz highlighted near-term value driving milestones, such as interim data coming at the beginning of next quarter and topline data in … <\/p>\n

Continue reading “GRI Bio Participates in a Virtual Investor CEO Connect Segment”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827003","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGRI Bio Participates in a Virtual Investor CEO Connect Segment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRI Bio Participates in a Virtual Investor CEO Connect Segment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Access the CEO Connect segment\u00a0 here LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc.\u00a0(NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, President and CEO of GRI Bio participated in a Virtual Investor CEO Connect segment. As part of this segment, Dr. Hertz provided an overview of GRI\u2019s lead program, GRI-0621, for Idiopathic Pulmonary Fibrosis (IPF), a rare chronic, progressive fibrosing interstitial lung disease with limited treatment options. Dr. Hertz highlighted near-term value driving milestones, such as interim data coming at the beginning of next quarter and topline data in … Continue reading "GRI Bio Participates in a Virtual Investor CEO Connect Segment"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T13:18:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GRI Bio Participates in a Virtual Investor CEO Connect Segment\",\"datePublished\":\"2025-03-18T13:18:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/\"},\"wordCount\":880,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/\",\"name\":\"GRI Bio Participates in a Virtual Investor CEO Connect Segment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA==\",\"datePublished\":\"2025-03-18T13:18:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRI Bio Participates in a Virtual Investor CEO Connect Segment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRI Bio Participates in a Virtual Investor CEO Connect Segment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/","og_locale":"en_US","og_type":"article","og_title":"GRI Bio Participates in a Virtual Investor CEO Connect Segment - Market Newsdesk","og_description":"Access the CEO Connect segment\u00a0 here LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc.\u00a0(NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, President and CEO of GRI Bio participated in a Virtual Investor CEO Connect segment. As part of this segment, Dr. Hertz provided an overview of GRI\u2019s lead program, GRI-0621, for Idiopathic Pulmonary Fibrosis (IPF), a rare chronic, progressive fibrosing interstitial lung disease with limited treatment options. Dr. Hertz highlighted near-term value driving milestones, such as interim data coming at the beginning of next quarter and topline data in … Continue reading \"GRI Bio Participates in a Virtual Investor CEO Connect Segment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T13:18:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GRI Bio Participates in a Virtual Investor CEO Connect Segment","datePublished":"2025-03-18T13:18:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/"},"wordCount":880,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/","name":"GRI Bio Participates in a Virtual Investor CEO Connect Segment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA==","datePublished":"2025-03-18T13:18:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjA2MiM2ODEwNDkwIzUwMDA3NTQ4OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-participates-in-a-virtual-investor-ceo-connect-segment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GRI Bio Participates in a Virtual Investor CEO Connect Segment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827003"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827003\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}